On December 13, 2024, Innovent Biologics, Inc. (HKG: 1801) registered a Phase I clinical trial for IBI3009 on the drug clinical trial registration and information public platform. The trial will investigate the efficacy of IBI3009 in treating small cell lung cancer (SCLC) and other neuroendocrine tumors.
Exploring Biomarkers and Efficacy of IBI3009
According to the registration information, the trial aims to explore the relationship between tumor DLL3 and SLFN11 expression levels and the efficacy of IBI3009. IBI3009 is identified as a DLL3 antibody-drug conjugate (ADC), with SLFN11 being a biomarker associated with the efficacy of topoisomerase I inhibitors (TOP1i).
DLL3 as a Key Target in SCLC and Innovent’s Pipeline
DLL3 is an important target in small cell lung cancer, and Innovent Biologics has also laid out DLL3/CD3 bispecific antibody IBI115 in its pipeline. The company has multiple ADC drugs that have entered clinical stages, covering a range of targets including HER2, Claudin18.2, B7H3, DLL3, Trop2, HER3, and EGFR/B7H3.-Fineline Info & Tech
